Compare Davita Inc (DVA) vs Jabil Inc (JBL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Davita Inc vs Jabil Inc — how do they compare? Davita Inc trades at $179.05 (market cap $11.29B), while Jabil Inc trades at $305.6 (market cap $31.35B). The key difference: Jabil Inc is far larger — about 2.8× Davita Inc's market cap, and Jabil Inc pays a 0.11% dividend while Davita Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Davita Inc for 114 Days and Jabil Inc for 23 Days on average.
| DVA | JBL | |
|---|---|---|
Market Cap | $11.29B | $31.35B |
Volume | 582,204 | 1,337,978 |
Sector | Health | Technology |
52-Week High | $240.96 | $385.50 |
52-Week Low | $103.87 | $192.49 |
Typical Hold Time | 114 Days | 23 Days |
Enterprise Value | $24.01B | $33.63B |
Dividend Yield | — | 0.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DaVita (DVA) trades at $179.02, up 1.26% with consistent earnings beats in recent quarters. The stock shows bearish technical signals but maintains strong fundamentals with 6.05% net margins and 635% ROE. Recent partnerships with Humana expand value-based kidney care services, while institutional investors like BlackRock added significant positions. Revenue growth remains steady at $13.6B annually with improving profitability trends.
DVA presents a mixed outlook with strong operational performance offset by technical weakness. The 43% upside to consensus price target of $235.67 offers potential, but high debt levels and regulatory risks require monitoring. Recent earnings momentum and expanding Medicare partnerships support long-term growth, though current technical indicators suggest near-term consolidation.
JBL trades at $305.83, up 2.12% with strong Q4 2026 earnings beating estimates at $4.40 EPS versus $4.07 expected. Technical indicators show bearish signals with price near resistance at $304, while fundamentals reveal robust revenue growth to $36.0B projected for 2026 and a high ROE of 74.11%. Recent news highlights AI infrastructure demand driving fiscal 2027 growth targets of 24%.
The outlook is positive with analyst consensus price target of $434.75 implying 42% upside, supported by 14 buy ratings and no sells. Risks include high debt levels and market volatility despite strong earnings, but AI-driven expansion and consistent earnings beats present a compelling growth opportunity for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Davita Inc
DaVita is the largest provider of dialysis services in the United States, boasting market share that eclipses 35% when measured by both patients and clinics. The firm operates over 3,100 facilities worldwide, mostly in the U.S., and treats over 240,000 patients globally each year. Government payers dominate U.S. dialysis reimbursement. DaVita receives approximately 69% of U.S. sales at government (primarily Medicare) reimbursement rates, with the remaining 31% coming from commercial insurers. However, while commercial insurers represented only about 10% of the U.S. patients treated, they represent nearly all of the profits generated by DaVita in the U.S. dialysis business.
Read more on DVA →About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →
